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Abstract
A twenty-seven year old woman who suffered a severe traumatic brain injury (TBI) 10 years ago is the patient of 
this study. She has had a generalized spasticity on the right side presenting between 40 and 50 spasm crises by day, 
as well as cognition deficit, increased tonus and stiffness. Thus, our objective was to evaluate the therapeutics effects 
of a cannabis extract on this clinical condition. The clinical evaluation points were at days 7, 14, 45, 75, 105, 135 and 
165. Spasms crises were evaluated 15 days before the treatment and 15 days after the start of treatment. Patient 
received microdose of cannabinoids for six months. The initial dose was around 170 µg of THC and 28 µg of CBD, 
dropping to 52 µg of THC and 7 µg of CBD by the end of treatment. The treatment reduced number of spasm, muscle 
tone, hyperreflexia and stiffness. Further, this treatment improved her cognition, short-term memory, speech, sense 
of humor, sleep and quality of life globally. This study shows for the first time that a very low dose of THC/CBD, in 
the order of micrograms, presented therapeutic effect in a human. Also, the ratio 6:1 between THC and CBD of this 
treatment is a new and interesting data to support new researches including cannabinoids and spastic syndrome.
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Spasticity is defined as a set of involuntary muscle 
hyperactivity, which consists of sensu strictu spasticity, 
stiffness, dystonia or spasm or a mixture of these. This 
muscular hyperactivity is related to different etiologies 
and its complications are strong contractures and pain 
[1]. For instance, spasticity can be a primary symptom 
of multiple sclerosis (MS), or induced by traumatic brain 
injury (TBI). When spasticity is a consequence of MS, 
there is a lesion of the myelin sheath, caused by immune 
mediated destruction of oligodendrocytes from the white 
motor fibers (axon of the superior motor neuron). While, 
when spasticity is induced by TBI, there is a cortical lesion 
at the level of the upper motor neuron cellular bodies [2-
4]. 
Pharmacological and surgical options to treat 
spasticity are available, but there is no consensus 
among experts regarding which one is the best option 
as a primary standard. Therefore, the type of treatment 
is generally decided on a case by case basis, making 
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this a controversial issue, due to the wide variation of 
how patients respond to each treatment [5]. Current 
pharmacological treatments usually have low efficacy, 
require high doses and often induce considerable side 
effects. Examples of usual treatments for spasticity are 
baclofen, gabapentin, pregabalin, diazepam, dantrolene 
and tizanidine [6]. Botulinum toxin presents good 
effectiveness for stiffness and spasm, but it does not 
present the same result for sensu strictu spasms [1]. 
In recent years, the Cannabis-based product Sativex 
has come to the market as an interesting novel resource 
for the neurologists and patients. Sativex is composed 
by cannabinoids, mainly tetrahydrocannabinol (THC) 
and cannabidiol (CBD) in a 1:1 ratio, with 27 mg/ml 
of THC and 25 mg/ml of CBD.  It is administered as an 
oromucosal spray with clinical indication for MS-induced 
spasms [7-14]. Sativex has been shown to improve 
spasms, hypertonia, stiffness, hyperreflexia and pain in 
MS patients. It also improves patient’s quality of life and 
presents mild side effects, such as somnolence, nausea, 
diarrhea and anxiety that can usually be reduced by 
titration dose [11,13-16]. Although the antispasmodic 
mechanism of Sativex is not yet fully elucidated, this 
effect is associated to the THC-induced activation of the 
CB1 cannabinoid receptors [14,17,18], which is consistent 
with data gathered in animal models of spasticity [19]. 
THC and CBD are the two most studied biological 
active phytocannabinoids from the Cannabis plant. 
THC, besides acts mainly through direct activation of 
cannabinoid receptor 1 (CB1) and cannabinoid receptor 
2 (CB2), appears to be epigenetically related by histone 
acetylation in synaptogenic mechanisms [20]. CBD has 
multiple mechanisms of action, including enhancement 
of endocannabinoid levels, allosteric inhibition of CB1 
receptors internalization [21], allosteric modulation of 
CB2 receptors [22] and even off-target receptors in the 
adenosinergic and serotoninergic systems [23,24]. CBD 
can antagonize some undesirable effects of THC, such as 
intoxication, sedation and tachycardia, while contributes 
to analgesic, antiemetic and anticarcinogenic THC 
properties [17]. Therefore, treatments with combined 
THC/CBD products tend to be more tolerated and 
effective than pure THC or CBD [25,26]. 
Regarding cannabinoid doses, although there are 
no studies evaluating cannabinoids microdoses in 
humans, some in vitro and in vivo studies have suggested 
this potential [20,27-31]. It has been shown that THC 
can activate cannabinoid receptors with a nano and 
micromolar range dose [27,28] and also it can induce 
biochemical and behavior changes in animals with very 
low doses [20,27-31]. 
Despite cannabinoids effective results on spastic 
syndrome induced by MS, these drugs have not yet 
been evaluated on spastic syndrome induced by TBI. 
It is important to mention that, although, the spastic 
syndrome has distinct etiologies when induced by MS 
or TBI, both are consequence of primary motor neuron 
lesion [2-4]. 
Our hypothesis was that microdoses of THC/CBD may 
cause clinical improvement in spastic syndrome from TBI, 
including reducing the number of spasms. Therefore, 
our objective was to describe the clinical effects of a 
microdose Cannabis extract (THC/CBD) experienced by 
the patient mentioned in this study.
Case Presentation 
The patient
The patient of our study is a 27 years old, woman, who 
has a history of severe traumatic brain injury (TBI) due to 
a car accident 10 years ago. The accident left the patient 
with an after-effect of generalized spasticity, which is 
more accentuated on the right side. At first visit, she 
presented partial dependence to perform daily activities. 
The neurological examination pointed out the classic 
clinical signs of the spastic syndrome: increased tonus, 
stiffness and medial torsions in the muscles of the upper 
and lower limbs (especially elbow, wrist and ankle joints), 
contributing to her dysfunctional gait (Wernicke-Mann 
posture). 
She had between 40 and 50 spasm crises per day on 
average, containing mild and severe spasms, with strength 
limitation of limbs, pain and increased resistance to 
mobilization in joints (mainly on the right side). Also, she 
had hyperreflexia of the physiological reflexes (patellar, 
aquilles, biceps, triceps) and pathological reflexes 
presented bilaterally (Tromner, Hoffman and Babinski). 
During the clinical examination, it was noticeable that 
she had language dysfunction, dysarthria and difficulty 
to understand complex sentences.
 
Quantification of cannabinoid compounds in 
the product
The quantification of cannabinoids present in the 
Cannabis extract was performed via a standard method 
using high performance liquid chromatography (HPLC) 
with a diode-array UV-VIS detector (DAD), adapted 
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from [32]. The methods used here are described in 
the analytical monograph from the Office of Medicinal 
Cannabis (Netherlands) and were already used in peer-
reviewed publications [33].
Treatment history and general procedures
Firstly, we counted the number of patient spasms for 15 
days before the beginning of the treatment. The patient 
took the treatment at home, helped by her caregiver, and 
came twice in the first month and once in the following 
months to be evaluated by a neurologist from our team. 
The current follow-up period of this patient is 6 months. 
She started taking 10 drops once per day for 1 month, 
following the maximum suggested dose in the product 
label. As the results were good, objectifying evaluate the 
effective level dose, we reduced the doses to 6 drops in 
the next month and to 3 drops in the last 3 months of her 
treatment.
 Evaluation of spasticity, spasms and pain 
The clinical evaluation of spastic syndrome was 
performed by examinations on the right and left 
hemisphere limbs using the Modified Ashworth Scale and 
Pen spasm scale [3,34]. The evaluations occurred one day 
before the beginning of treatment (T0) and on days 7, 14, 
45, 75, 105, 135 and 165 henceforth called T1, T2, T3, T4, 
T5, T6 and T7, respectively. The number of spasms crisis 
of the right upper limb was evaluated for 15 days prior to 
treatment (-15 to 0 day) and 15 days after the beginning 
of treatment (0 to 15th day). The spasms were classified 
by intensity (mild and severe), and counted daily by the 
caregiver. The patient pain level was assessed by the 
visual analogue scale of pain application [35].
Evaluation of cognitive improvements
When we planned the design study, the cognition 
evaluation was not included in our objective list. However, 
after some weeks we clearly noted the beginning of some 
patient cognition improvements. Then, we systematized 
cognition parameters collecting data from our clinical 
observations and from the caregiver reports.
Evaluation of side effects
Anxiety and depression scores were evaluated using 
the Brazilian Portuguese validated Hospital Anxiety 
and Depression Scale (HADS) questionnaire [36] for the 
primary purpose of verifying any potential side effect. 
Further, in all time points evaluation (T0 to T7) the patient 
was encouraged by our team to relate any possible side 
effect.
 Results 
 Quantification of cannabinoid compounds in 
the product
The concentrations in the sample were obtained by 
extrapolation from the areas under the curve for each 
identifiable peak of the chromatograms with the aid 
of standard curves using reference standard material 
for each analyte, as shown in Figure 1. The estimated 
concentration in the product (weight/volume) is below 1% 
for any of the main cannabinoids we tested (CBD, THC, 
CBG, CBC, THCA, CBDA and CBN) and below the detection 
limit for any cannabinoid other than THC and CBD. The 
only identifiable peaks of cannabinoid molecules were 
THC (RT 6.95) and CBD (RT 3.52).
An unknown molecule was detected at RT 9.6 
which one we consider very improbable to induce 
any pharmacological effect due to its negligible 
concentrations. CBD was present in the sample at the 
very low concentration of 0.006% and THC was present 
at a concentration of 0.035%. 
Extrapolating from the amounts taken by the patient 
along the treatment period and based on the extract 
concentration of THC/CBD, we estimate that the 
patient initiated treatment with 170/28 µg of THC/CBD 
(equivalent to 10 drops, around 500 µl orally) in the 1st 
month, reduced to 100/17 µg of THC/CBD in the 2nd 
month (6 drops, around 300 µl orally) and ended up 
taking only 52/9 µg of THC/CBD per day (3 drops, around 
150 µl orally) during the last 4 months of treatment. 
Either of these doses is extremely low, and to the best of 
our knowledge, this is the first report of clinically-relevant 
effects of cannabinoid compounds in this dose range.
Spasms, spasticity and pain
The patient presented a marked reduction in the 
number of spasms over the course of the treatment. The 
number of spasms before the treatment and after the 
initiation of the treatment, was significantly different (p 
< 0.001, Student’s T test). After the 15th day of treatment 
until the end of the study the number of spasms crisis 
was never higher than 2 per day. Number of mild (A) and 
severe spasms (B) in the right upper limbs observed for 
15 days before the treatment and for 15 days after the 
beginning of the treatment. In panel A the mean and the 
standard error of the median (SEM) of the pre-treatment 
and post-treatment period was 23.13 ± 1.22 and 10.40 ± 
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2.20, respectively. In panel B the mean and the SEM of 
the pre-treatment and post-treatment period was 20.67 
± 0.99 and 7.27 ± 2.24, respectively (Figure 2).
Figure 1: Chemical analysis of the THC-rich cannabis 
extract.
In general, the treatment induced a remarkable 
improvement in spasticity, including tonus, stiffness, 
spasms, physiological and pathological reflexes, motor 
and daily activities. These improvements resulted in an 
enhancement in her functional independence and in a 
substantial improvement in her quality of life. 
As shown in Table 1, the Cannabis extract also 
substantially reduced the most signals and symptoms 
induced by spastic syndrome according to the Modified 
Ashworth Scale.  In addition, the treatment induced a 
marked reduction of the spasms on Peen scale on right 
upper limb. At T0 the patient presented mild spastic 
hypertonia in the left hemibody, which was also reduced 
by treatment. It was also observed a reduction in the 
physiological reflexes of the upper and lower limbs that 
were previously exacerbated. The pathological reflexes 
of Trommer and Babinski remained present during the 
study, except the Babinski reflex that was absent at T6 
clinical examination. 
Figure 2: Antispasmodic activity of a microdose of THC-
rich cannabis extract.
In addition, the treatment induced significant 
improvements regarding her dysarthria, gait, ability 
to get on and off the stretcher, ability to remove and 
wear the shoes. According to the caregiver’s report (in a 
free translation to English): “...she presented significant 
improvement in activities, such as dressing on her own, 
moving around the house easily, using the right side 
to feed herself independently, applying makeup on 
herself and writing.  She is getting autonomy in her daily 
activities”...
Regarding the pain levels, the patient did not report 
spontaneous spasmodic pain at T0, although she used 
to present a light pain during the neurological exam 
mobilizations. A discrete reduction in the level of pain 
induced by the mobilizations performed in the limbs 
during the neurological physical examination was verified. 
We suggest that this pain improvement was induced by 
tonus and stiffness reduction.
 Cognitive improvements and side effects
After some weeks, we clearly noted the beginning 
of some improvement on patient’s cognition. The 
improvement of the patient cognitive skills was 
remarkable, especially after the third week of treatment. 
330 J Pharm Sci Therap, 5(1): 326-335 (2019)  




T0 T1 T2 T3 T4 T5 T6 T7
Tonus 4 3 1+ 0 1 1 1 1
Spasms 4 3 1 1 1 1 1 no
Reflexes hyperreflexia of 
biceps, radial and 
palmar
hyperreflexia 











of biceps and 
radial
hyperreflexia 









yes yes yes yes yes yes yes yes
Joint stiffness † † † † † † no † † † †
Degree of 
Strength
3 3 3 4 4 3 3 4
Right Lower 
Limb
T0 T1 T2 T3 T4 T5 T6 T7
Tonus 3 2 1+ 1+ 1+ 1 1+ 1
Spasms No No No No No No No No
Reflexes hyperreflexia 




















(Babinski signal)  
yes yes yes yes yes yes no yes
Joint stiffness † † † † † † † † †
Degree of 
Strength
3 3 4 4 4 4 4 4
Left Upper 
Limb
T0 T1 T2 T3 T4 T5 T6 T7
Tonus 1+ 1 0 0 0 0 0 0
Spasms no no no no no no no no
Reflexes hyperreflexia 
of triceps and 
biceps
hyperreflexia 






of triceps and 
biceps
hyperreflex-

















yes yes yes yes yes yes no no
Pathological 
reflex      
(Hoffman) 
yes yes yes yes yes yes yes yes
Joint stiffness † † no no no no no no
Degree of 
Strength
4 4 4 4 4 4 4 4
Left Lower 
Limb
T0 T1 T2 T3 T4 T5 T6 T7
Tonus 1 1 1 1 1/0 2/1. 1/0 0
Spasms no no no no no no no no
Reflexes hyperreflexia 





















yes yes yes yes yes yes no yes
Joint 
stiffness
† † † † † † no †
Degree of 
Strength
4 4 4 4 4 4 4 4
Tonus was evaluated according to Modified Ashworth Scale (from 0 to 4). Spasms was evaluated according to Peen scale (from 0 to 4). Legend of 
the signals: † † † (intense); † † (moderate); † (light).
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This became clearly noticeable when she was answering 
the HADS questionnaire. Until the T0, T1 and T2, she 
could not answer the questionnaire by herself because 
of her neurologic condition. However, she surprised 
us at T3, when she spontaneously took the sheets and 
answered the questionnaire by herself, with no need 
of the researcher’s supervision or instructions. After 
that, we decided to systematize the data collection of 
cognition parameters, including our clinical observations 
and reports from the caregiver.
According to the information shown on Table 2, the 
patient presented improvements in text interpretation, 
thought, cognitive processing to choose an answer 
(questionnaire), fine motor coordination and ability to 
understand and elaborate sentences and speech. In 
addition, the patient presented improvement in her 
ability to communicate in oral and written language (also 
observed during our interviews and clinical examinations).
Regarding effects of this treatment on patient’s 
memory, in an interview without the patient presence, 
the caregiver reported that the patient recovered 
old memories (in an English free translation): “...she 
remembered events that occurred immediately before (a 
couple of months) the car accident which had induced her 
condition. These memories had been completely forgotten 
and were never mentioned by her after the accident”. This 
kind of reports were already cited in the literature by 
Cannabis non-medicinal users [37]. 
The caregiver also reported that the patient presented 
a considerable increase in short-term memory after the 
treatment: “... before the treatment, when she asked me 
for ice cream, I used to say that I would buy it on the next 
day and, at the next day, she usually did not remember 
my promise anymore. Now, whenever I promise ice 
cream, the day after, she remembers and demands me 
to fulfil the promise”. Although these improvements were 
not analyzed by objective clinical protocols, they strongly 
corroborate to the patient’s clinical history.
Table 2: Observation of the evolution of cognition skills. 
Cognition 
reports






questions. It is 
necessary to read 
and repeat the 
questions many 
times.
She does not 
understand well 
the 
questions. It is 
necessary to
 repeat the 
questions some 
times.
She does not 
understand well 
the questions. It 
is still necessary 





She barely holds 
the questionnaire 






She holds the 
questionnaire 
and answer it 





naire. She holds 
the question-
naire and answer 
it by herself.
She under-
stands well the 
questionnaire. 
She holds the 
questionnaire 
and answer it by 
herself.
Pen use During the 
questionnaire the 
researcher uses 
the pen to fill the 
questionnaire 






the pen to fill the 
questionnaire 





the pen to fill the 
questionnaire 
according to the 
patient answers
She holds the pen 
by the first time 
and fill part of the 
questionnaire.
She holds the 
pen and easily 
fill up all the 
questionnaire.
She holds the 
pen and easily fill 
up all the ques-
tionnaire.
She holds the 
pen and easily 




the writes her 
name within a 
small space of 



































No other reports Patient reports 
improvement of 
quality of sleep 
and a "morning 
hapiness"








She begins to 
read a book by 
the first time 
after the TBI
She starts to 
feed by herself 
with the right 
hand
Observation of capacity of comprehension, fine motor activity, speech and other cognition skills of patient.
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Throughout the duration of the study, the only 
side effects observed were light diarrhea and some 
somnolence in the first week of treatment, according to 
the caregiver’s description. After that, neither the patient 
nor her caregiver related any side effect. The occurrence 
of common side effects related to cannabinoid treatments 
like increase of appetite, dizziness or sleepiness was 
specifically asked at each clinical examination, but the 
answer was negative. 
Additional reports from the caregiver were the absence 
of daily complaints of headaches and the improvement in 
the quality of sleep. The lack of any relevant side effect 
is easily explained by the cannabinoids very low doses 
used. Regarding the HADS questionnaire application, 
anxiety and depression scores were at subclinical levels 
at the baseline and they remained like until the end of 
treatment (data is not shown).
Discussion and Conclusion
In this study, the treatment of a spastic syndrome 
patient who received a microdose of a Cannabis extract 
presented the main highlights: i) THC/CBD microdosing 
(170/28 - 52/9 µg/day, p.o.) improved on patient’s spastic 
symptoms, as well as cognition and quality of life; ii) the 
treatment used was devoid of any significant adverse 
effect, and iii) to the best of our knowledge, this is the 
first objective study in the scientific literature showing 
therapeutic effects of THC/CBD in a true microgram dose-
range in human patients.
Although the etiology of the spastic syndrome of the 
patient evaluated in this case report is distinct from the 
spasms of the patients evaluated in most of the Sativex 
studies [8-14,38], it is interesting to comment that THC/
CBD doses used here are several times lower than the 
usual ones. According to the manufacturer data, Sativex 
is a solution containing 27 mg/ml of THC and 25 mg/ml 
of CBD, i.e., a 1:1 ratio. Usually, Sativex patients use an 
average of 8 sprays per day, which is around 20 mg of each 
cannabinoid per day [12,39,40]. The product analyzed in 
this study contained only 0.35 mg/ml of THC and 0.06 mg/
ml of CBD (Figure 2). At the first month of the treatment 
the patient received approximately 500 µl/day of product, 
containing less than 200 µg of THC and 6 times less CBD. 
This is over 100 times less drug in comparison to Sativex 
with noticeable evidence of efficacy. 
Despite the obvious limitations of this study, the 
consistency of the clinical data over 6 months of 
treatment motivated us to report this clinical case. These 
results are important evidences suggesting by the first 
time that microdose of THC/CBD could indeed be used 
to treat spastic symptoms in humans and it deserve to be 
further investigated. 
Although there is no clinical study showing that 
cannabinoids microdoses can induce therapeutic effects, 
some in vitro and in vivo studies support our data. Has 
been shown that THC is able to activate CB1 and CB2 
receptors, within Ki values in the nano and micromolar 
concentration range [27,28,41]. Further, in vivo studies 
has demonstrated that very low and ultra low doses 
of THC, such as 0.002 mg/kg, induces improvement in 
memory, learning and cognitive parameters in mice 
[29-31,42,43]. Another study describes the effects of 
micromolar and nanomolar concentrations of THC and 
CBD at modulation of the mitogen-induced tryptophan 
degradation and neopterin formation in peripheral 
blood mononuclear cells, correlating these effects with 
the serotoninergic system and psychiatric disorders, like 
depression [28].
Our positive results on patient cognition with such a low 
dose of THC/CBD is a human evidence in support of recent 
animals studies showing that low doses of THC improves 
memory and restores synaptogenesis in rats [20,27-
31,42,43]. Although there are studies trying to make clear 
the relationship between neurotoxic and neuroprotective 
effects and high or low doses of cannabinoids [44], we 
think that this may be more complex and unpredictable. 
Regarding THC, its neuroprotective effects seem to be 
related to the production of neurotrophins, such as brain 
derived neurotrophic factor (BDNF), axonal and synaptic 
proteins, as well as the reduction of inflammatory factors 
and inflammatory responses that lead to neuronal death 
[20,27-31,42,43].
The range cannabinoid dose used here is in line with 
previous evidence, showing that THC begins to present 
substantial psychoactive effects at oral doses starting 
from 30 mg, which is around 200 times over the dose 
reported here. Moreover, severe addictive effects such 
as irritability, mood and sleep alterations have only been 
reported in chronic heavy users at doses above 150 mg/
day [45]. The results here reported yielded the hypothesis 
that microdoses of THC/CBD are clinically effective for 
human patients with neurological disorders. Further, 
according to our observation and previous clinical data, 
we believe that this dose range is absolutely safe. At least, 
there is no reason to believe that Cannabis induces any of 
its typical effects at the microdose range. 
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In conclusion, this study shows that a microdose of 
THC/CBD in a 6:1 ratio can be a potential treatment to 
spastic syndrome induced by TBI. This range of dosage 
seems to be able to improve cognitive deficit and quality 
of life globally. Further, this microdose of THC/CBD does 
not induce any significant side effects.
Finally, extrapolating the results found in this case 
study and based on many animal studies, we hypothesize 
that doses of cannabinoids, mainly THC, in microdose 
range, can be therapeutically effective in humans and, in 
the near future, will open a great avenue on cannabinoid 
clinical studies.
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